Who
Jason Aryeh
Director
Company insider
Files Form 4 as: Director, Orchestra BioMed Holdings; Director, Ligand Pharmaceuticals; Director, Lifecore Biomedical; Director, Anebulo Pharmaceuticals; Insider, Merrimack Pharmaceuticals; Director, Aralez Pharmaceuticals; Director, Novelion Therapeutics; Director, Immunomedics.
In numbers
- Trades disclosed
- 393
- Buys
- 61
- Sells
- 73
- Bought
- $5.6M
- Sold
- $41.0M
- Companies
- 10
- Companies where not an officer
- 10
- First trade
- 27 Sep 2006
- Last trade
- 23 Jun 2026
- Last filed
- 25 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jun 2026filed 25 Jun 2026 | OBIO Orchestra BioMed Holdingsoption or derivative · Medical Devices | SEC FORM 4 Code A | —42,553 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | OBIO Orchestra BioMed Holdingsoption or derivative · Medical Devices | SEC FORM 4 Code A | —42,553 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.1M4,500 at $250.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.1M4,500 at $250.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $125K500 at $250.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $125K500 at $250.00 | filing |
| 5 Jun 2026filed 12 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —836 at $0.00 | filing |
| 5 Jun 2026filed 12 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,938 at $0.00 | filing |
| 5 Jun 2026filed 12 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,938 at $0.00 | filing |
| 5 Jun 2026filed 12 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —836 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | LFCR Lifecore BiomedicalBiotechnology | SEC FORM 4 Code A | —25,907 | filing |
| 4 Jun 2026filed 5 Jun 2026 | LFCR Lifecore BiomedicalBiotechnology | SEC FORM 4 Code A | —25,907 | filing |
| 18 May 2026filed 20 May 2026 | OBIO Orchestra BioMed HoldingsMedical Devices | SEC FORM 4 Bought | $2,494665 at $3.75 | filing |
| 18 May 2026filed 20 May 2026 | OBIO Orchestra BioMed HoldingsMedical Devices | SEC FORM 4 Bought | $2,494665 at $3.75 | filing |
| 15 May 2026filed 19 May 2026 | OBIO Orchestra BioMed HoldingsMedical Devices | SEC FORM 4 Bought | $35K8,971 at $3.90 | filing |
| 15 May 2026filed 19 May 2026 | OBIO Orchestra BioMed HoldingsMedical Devices | SEC FORM 4 Bought | $35K8,971 at $3.90 | filing |
| 8 Dec 2025filed 8 Dec 2025 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,034 at $0.00 | filing |
| 8 Dec 2025filed 8 Dec 2025 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $141K2,034 at $69.51 | filing |
| 23 Sep 2025filed 24 Sep 2025 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $753K4,418 at $170.41 | filing |
| 23 Sep 2025filed 24 Sep 2025 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $791K4,628 at $170.96 | filing |
News
Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Ligand Pharmaceuticals (NASDAQ:LGND)LGND · tickerreport.com · 23 Oct 2026Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SABOBIO · manilatimes.net · 22 Oct 2026
0 headlines in the last 90 days name Jason Aryeh; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.